Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 23 09:55AM ET
0.6615
Dollar change
-0.0156
Percentage change
-2.30
%
Index- P/E- EPS (ttm)-0.95 Insider Own0.56% Shs Outstand79.94M Perf Week3.46%
Market Cap52.88M Forward P/E- EPS next Y-0.93 Insider Trans0.00% Shs Float79.50M Perf Month-52.07%
Income-60.61M PEG- EPS next Q-0.29 Inst Own1.40% Short Float0.74% Perf Quarter-51.72%
Sales4.80M P/S11.02 EPS this Y-15.02% Inst Trans128.85% Short Ratio1.38 Perf Half Y-51.36%
Book/sh0.18 P/B3.62 EPS next Y9.71% ROA-86.40% Short Interest0.59M Perf Year-41.46%
Cash/sh0.54 P/C1.23 EPS next 5Y- ROE-189.23% 52W Range0.61 - 2.53 Perf YTD-57.87%
Dividend Est.- P/FCF- EPS past 5Y21.53% ROI-286.71% 52W High-73.85% Beta1.50
Dividend TTM- Quick Ratio1.47 Sales past 5Y0.00% Gross Margin8.96% 52W Low8.44% ATR (14)0.08
Dividend Ex-Date- Current Ratio1.53 EPS Y/Y TTM-93.34% Oper. Margin-895.65% RSI (14)32.10 Volatility7.73% 10.47%
Employees38 Debt/Eq0.88 Sales Y/Y TTM- Profit Margin-1262.79% Recom1.00 Target Price13.75
Option/ShortYes / Yes LT Debt/Eq0.60 EPS Q/Q-105.91% Payout- Rel Volume1.42 Prev Close0.68
Sales Surprise3100.00% EPS Surprise13.64% Sales Q/Q- EarningsMar 26 BMO Avg Volume427.62K Price0.66
SMA20-18.37% SMA50-37.01% SMA200-53.81% Trades Volume67,434 Change-2.30%
Date Action Analyst Rating Change Price Target Change
May-18-17Upgrade Maxim Group Hold → Buy $1 → $3
Feb-13-17Initiated Rodman & Renshaw Buy $3
Aug-12-16Downgrade Maxim Group Buy → Hold $4 → $1
Aug-17-15Reiterated Maxim Group Buy $8 → $4
Jul-27-15Reiterated ROTH Capital Buy $10.50 → $7
Jun-22-15Initiated JMP Securities Mkt Outperform $5
Apr-17-24 07:00AM
Apr-10-24 07:00AM
Apr-01-24 09:00AM
Mar-27-24 12:23PM
Mar-26-24 07:00AM
07:00AM Loading…
Mar-20-24 07:00AM
Mar-06-24 08:00AM
Mar-04-24 07:00AM
Feb-28-24 07:00AM
Feb-25-24 02:12PM
Feb-16-24 07:00AM
Dec-21-23 07:00AM
Nov-21-23 03:45PM
Nov-20-23 07:00AM
Nov-13-23 07:00AM
03:12PM Loading…
Nov-02-23 03:12PM
Oct-31-23 09:00AM
Oct-30-23 11:38AM
Oct-12-23 07:00AM
Sep-28-23 07:00AM
Sep-19-23 07:00AM
Sep-14-23 05:36AM
Sep-11-23 07:00AM
Sep-05-23 06:04AM
Aug-31-23 08:18AM
Aug-30-23 07:00AM
Aug-22-23 07:00AM
Aug-07-23 02:34PM
Jul-18-23 03:22PM
Jul-17-23 07:00AM
02:00PM Loading…
Jun-29-23 02:00PM
Jun-07-23 05:25AM
May-24-23 07:00AM
May-17-23 07:00AM
May-04-23 01:56PM
Apr-25-23 07:00AM
Apr-17-23 11:00AM
Apr-04-23 08:21PM
Mar-24-23 07:15AM
Mar-23-23 11:42AM
Mar-22-23 07:00AM
Mar-15-23 07:00AM
Mar-06-23 07:00AM
Jan-04-23 07:00AM
Dec-20-22 12:36PM
07:00AM
Dec-05-22 04:00AM
Nov-28-22 04:30PM
Nov-15-22 07:00AM
Nov-10-22 04:30PM
07:00AM
Nov-04-22 04:30PM
Nov-03-22 09:11AM
Nov-02-22 09:21AM
Sep-27-22 07:00AM
Sep-19-22 08:00AM
Sep-15-22 12:38PM
07:00AM
Sep-12-22 07:00AM
Aug-18-22 07:47AM
Aug-16-22 07:00AM
Aug-11-22 07:00AM
Jun-29-22 08:00AM
Jun-28-22 07:00AM
Jun-16-22 07:00AM
May-12-22 10:16AM
May-11-22 07:00AM
May-05-22 07:00AM
Mar-17-22 08:55AM
Mar-16-22 07:00AM
Mar-10-22 07:00AM
Mar-03-22 07:00AM
Jan-31-22 04:20AM
Jan-24-22 07:00AM
Jan-18-22 07:00AM
Dec-17-21 07:00AM
Dec-15-21 07:00AM
Nov-18-21 07:00AM
Nov-12-21 07:16AM
Nov-04-21 09:15AM
Oct-13-21 08:30AM
Oct-06-21 04:38AM
Aug-18-21 07:00AM
Aug-12-21 09:30AM
Jun-30-21 08:58AM
Jun-04-21 09:04AM
May-26-21 07:00AM
May-20-21 07:00AM
May-04-21 08:56AM
08:19AM
07:00AM
Apr-15-21 07:14AM
Feb-23-21 07:45AM
07:00AM
Feb-17-21 07:00AM
Jan-28-21 11:31AM
Jan-22-21 04:15PM
Jan-19-21 09:42PM
04:55PM
Jan-07-21 09:28AM
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.